ICU Medical (NASDAQ: ICUI) reported Q3 EPS of $1.12, $0.35 better than the analyst estimate of $0.77. Revenue for the quarter came in at $343.24 million versus the consensus estimate of $329.29 million.

Fiscal Year 2017 Guidance Update and Initial Fiscal 2018 Guidance

The Company is modifying its full year 2017 guidance of adjusted EBITDA from a range of $180 million to $190 million to a range of $195 million to $205 million and adjusted earnings per share from a range of $3.80 to $4.20 to a range of $4.20 to $4.80. The Company is also providing initial 2018 adjusted EBITDA guidance in the range of $240 million to $260 million and initial 2018 adjusted EPS in the range of $6.05 to $6.65.

GUIDANCE:

ICU Medical sees FY2017 EPS of $4.20-$4.80, versus the consensus of $4.11.

ICU Medical sees FY2018 EPS of $6.05-$6.65, versus the consensus of $6.08.

For earnings history and earnings-related data on ICU Medical (ICUI) click here.